Working… Menu

Hepatic Impairment Study for Lorlatinib in Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03726333
Recruitment Status : Recruiting
First Posted : October 31, 2018
Last Update Posted : November 11, 2019
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : August 16, 2022
Estimated Study Completion Date : January 25, 2023